Document text
Principal Investigator: Caitlin Jaime Couch
Organization: EMORY UNIVERSITY
Fiscal Year: 2023
Award: $36,384
Funding agency: National Center for Complementary and Integrative Health
ABSTRACT
As of August 2021, the coronavirus disease COVID-19, caused by the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2), has infected more than 200 million people across the globe, causing more than
600,000 deaths in the USA and 4.2 million worldwide. Though vaccines have become available, vaccinated
individuals can still spread the disease to unvaccinated and vulnerable populations. As vaccination rates in the
United States remain low, emerging variants that may evade the vaccine are a new risk. Identifying novel
preventative agents from traditional medicine could lead to the development of a readily available, cost-effective,
and safe dietary intervention against COVID-19.
During the pandemic, individuals have turned to herbal supplements to prevent COVID-19. There are published
in silico studies and a few in vitro studies on these extracts, but the science to support natural products’ (NPs)
use to prevent viral infection is still incomplete. The Quave Natural Product Library (QNPL) is a collection of over
2,000 botanical and fungal extracts, including the 40 most used natural supplements in the USA. Viral entry, in
which SARS-CoV-2 attaches to the Angiotensin-Converting Enzyme 2 (ACE2) cell surface receptor found on
endothelial cells, pneumocytes (type 1 and 2), and ciliated bronchial epithelial cells, presents an attractive option
for preventatives. I have screened 2,000 extracts from the QNPL against SARS-CoV-
2 pseudotyped virus system to test which extracts inhibit viral entry. Mammalian cell cytotoxicity assays
measuring Lactate Dehydrogenase (LDH) formation were run in parallel to ensure inhibition was not due to cell
death.
This proposal employs a multi-faceted approach to identify agents with direct-acting antiviral properties using a
one-of-a-kind natural product library. Three extracts with potent bioactivity as direct-acting antiviral agents
without apparent toxicity were selected after screening the QNPL. Bioassay guided fraction coupled to LC-
MS/MS molecular networking analysis will be used for the identification of compounds with direct-acting antiviral
activity. Compounds will be further isolated using preparative HPLC and structurally elucidated by NMR and X-
crystallography to determine the absolute structure of the viral inhibitor. The fractions and isolated compounds
will be tested across emerging variants in relevant cell lines and in live virus to further understand activity.
Additionally, I will undertake mechanism of action studies utilizing biolayer interferometry and ELISA assays.
These studies will result in the identification of NPs with the potential to block SARS-CoV-2 viral entry in relevant
human cells, enhancing understanding of the preventative value of plant NPs for COVID-19 and other viruses.
This will enable formulation of a bioactive dietary supplement, prioritization of leads for a medicinal chemistry
campaign, and identification of tool compounds to query these pathways.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><A549><ACE2><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Binding><Bioassay><Biologic Assays><Biologic Sciences><Biological Assay><Biological Sciences><Bioscience><Botanicals><COVID><COVID-19><COVID-19 S protein><COVID-19 infection><COVID-19 prevention><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapy><COVID-19 treatment><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 S protein><COVID19 infection><COVID19 prevention><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cell Body><Cell Death><Cell Line><Cell Surface Receptors><Cell model><CellLine><Cells><Cellular model><Cessation of life><Chemical Fractionation><Chemicals><China><Chromatography><Ciliated Bronchial Epithelial Cell><CoV disease><CoV-2><CoV2><Collaborations><Collection><Communicable Diseases><Contracting Opportunities><Contracts><Coupled><Crystallographies><Crystallography><Data><Death><Development><Diet><Dietary Intervention><Disease><Disorder><Dose><EC 1.1.1.27><ELISA><Edible Plants><Endothelial Cells><Ensure><Enzyme-Linked Immunosorbent Assay><Epithelial Cells><Ethnobotany><Exhibits><FRACN><Food Plants><Formulation><Fractionation><Fractionation Radiotherapy><Goals><HPLC><Health Care Costs><Health Care Professional><Health Costs><Health Professional><Healthcare Costs><Healthcare professional><Herbal dietary supplement><Herbal supplement><High Performance Liquid Chromatography><High Pressure Liquid Chromatography><High Speed Liquid Chromatography><High Throughput Assay><History><Human><Immune response><Immunological response><In Vitro><Indigenous><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammatory><Interferometry><L-Lactate Dehydrogenase><L-Lactic Acid Dehydrogenase><Lactate Dehydrogenase><Lentivirinae><Lentivirus><Libraries><Life Sciences><Luciferase Immunologic><Luciferases><Lung><Lung Respiratory System><Lytotoxicity><Mainland China><Mammalian Cell><Measures><Medicinal Chemistry><Medicinal Plants><Medicine><Modeling><Modern Man><Molecular><Molecular Interaction><NAD-Lactate Dehydrogenase><Natural Products><Natural Supplement><Network Analysis><Nutrition Interventions><Nutritional Interventions><Pathway Analysis><Pathway interactions><Persons><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmacognosy><Plants><Plaque Assay><Population><Process><Property><Province><Publishing><Receptor Protein><Recording of previous events><Reporter><Research><Research Resources><Resistance><Resolution><Resources><Risk><Running><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Science><Serial Passage><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Single Crystal Diffraction><Standardization><Strains Cell Lines><Structure><Surface><System><Techniques><Testing><Therapeutic><Toxic effect><Toxicities><Traditional Medicine><United States><Vaccinated><Vaccination><Vaccinee><Vaccines><Variant><Variation><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Physiology><Virus><Virus Diseases><Virus Inhibitors><Vulnerable Populations><Wuhan coronavirus><X Ray Crystallographies><X-Ray Crystallography><X-Ray Diffraction Crystallography><X-Ray/Neutron Crystallography><Xray Crystallography><access to vaccination><access to vaccines><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><block viral entry><clinical relevance><clinically relevant><combat><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infection><coronavirus disease 2019 prevention><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 prevention><coronavirus disease-19 virus><coronavirus infectious disease-19><cost effective><cultured cell line><cytotoxicity><depository><derived from natural product><developmental><diet intervention><diet supplement><dietary><dietary supplements><diets><disease severity><efficacy validation><enzyme linked immunoassay><hCoV19><hesitant to vaccination><high throughput screening><histories><host response><immune system response><immunoresponse><in silico><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibit viral entry><insight><lactic acid dehydrogenase><meter><nCoV2><natural product derivative><natural product derived compound><naturally occurring product><naturally occurring supplement><necrocytosis><non vaccinated><not vaccinated><novel><nutritional supplement><pandemic><pandemic disease><pathway><pneumocyte><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><pulmonary><receptor><receptor binding><receptor bound><repository><resistant><resolutions><screening><screenings><secondary metabolite><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><symptom treatment><symptomatic treatment><tool><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treat symptom><unvaccinated><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccination access><vaccination availability><vaccination hesitancy><vaccine access><vaccine availability><vaccine hesitancy><vaccine hesitant><validate efficacy><viral entry blocker><viral entry inhibitor><viral infection><viral inhibitor><virus infection><virus-induced disease><vulnerable group><vulnerable individual><vulnerable people>